Increasing sensitivity and discrimination of breast cancer diagnosis using molecularly targeted, extravascular ultrasound imaging with ultrasound-activated, phase-change nanodroplet contrast agent
使用超声激活相变纳米液滴造影剂进行分子靶向血管外超声成像,提高乳腺癌诊断的灵敏度和辨别力
基本信息
- 批准号:9768466
- 负责人:
- 金额:$ 7.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcousticsBackBenignBiodistributionBiological AssayBiotinBloodBlood CirculationBlood VesselsBody TemperatureCaliberCarrying CapacitiesContrast MediaCustomDNADNA BindingDNA ProbesDetectionDevelopmentDiagnosisDiagnosticDiagnostic SensitivityDiscriminationDoseEncapsulatedEndothelial CellsExtravasationFDA approvedFluorocarbonsFormulationFutureGasesHalf-LifeImageImmunohistochemistryKidneyKnowledgeLabelLipidsLiquid substanceMalignant - descriptorMeasuresMethodsMicrobubblesMolecularMolecular TargetNormal tissue morphologyOrganPermeabilityPhasePhysiologic pulsePolymerase Chain ReactionProteinsPublic HealthReagentSignal TransductionSpecificityStainsTechniquesTemperatureTestingTimeTissuesTumor TissueTumor VolumeUltrasonographyVascular Endotheliumbreast cancer diagnosisbreast lesioncancer biomarkerscancer diagnosiscancer therapycontrast enhanceddensityimaging agentin vivointerstitialmalignant breast neoplasmmolecular imagingnanonanoDropletnanoparticlenanoscalenovelphase changepressurepreventtargeted agenttumor
项目摘要
ABSTRACT
Lipid shelled perfluorocarbon (PFC) microbubbles ranging from 0.5 to 8 microns in diameter have been
approved by the FDA to enhance the contrast of blood for diagnostic ultrasound imaging. The micro scale of
ultrasound contrast agents limits them to the bloodstream, eliminating the enhanced permeability and retention
(EPR) observed in many tumors. The ability to create nanoparticles from existing lipid-shelled microbubble
contrast agents lets us leverage the non-toxic formulations of these agents, and lets us create novel targeted
nanoparticles using any of the established strategies for formulating targeted microbubbles. Microbubbles
targeted to Secreted Frizzled Related Protein 2 (SFRP2) showed significant discrimination between tumor and
normal vasculature, and SFRP2 is highly expressed in a variety of breast cancers. We and our colleagues
found that cold and increased pressure caused conventional gas-phase ultrasound contrast to condense into
lipid-shelled nanodroplets of liquid PFC. With sufficient energy, these non-echogenic agents revert back to
conventional ultrasound contrast agents. Nanodroplets share the advantages inherent to nanoparticle
strategies for cancer therapy: passive accumulation in tumors enhanced by the EPR effect, targeted
accumulation within tumors aided by targeting moieties, and reduced systemic dosing. Activating nanodroplets
with ultrasound provides a high degree of spatial selectivity, preventing re-entry of the micro scale bubbles into
the vasculature, thus maintaining a high local concentration of contrast agent. Molecular imaging that
interrogates the interstitial space within tumors widens the physical scope of imaging with the payoff of a higher
density of bound contrast throughout the tumor volume, and additional opportunities to target tumor molecules
that are not found in the vascular endothelium. We propose that extravascular molecular imaging with SFRP2-
targeted nanodroplets will increase the sensitivity of detecting breast cancer compared to microbubble
molecular imaging while maintaining the molecular specificity needed to decrease false diagnoses. A critical
barrier to leveraging molecularly targeted, lipid shelled perfluorocarbon nanodroplets is a fundamental lack of
knowledge about their biodistribution in normal and tumor tissue. We propose to combine existing, established
techniques to create SFRP2-targeted, and non-targeted nanodroplet formulations carrying a biotin and DNA
label, determine their circulating half-lives, and use immunohistochemical detection of biotin or quantitative
polymerase chain reaction assays of our unique DNA payload to characterize the biodistribution of these liquid
perfluorocarbon droplets in normal and tumor tissues. Establishing the ability of targeted nanodroplets to cross
the endothelial cell layer leverages existing microbubble contrast agents, promotes development of novel nano
agents, and increases the impact of ultrasound for detecting breast cancer by developing a novel, highly
sensitive ultrasound method that leverages the discriminatory power of targeted molecular imaging in the
vascular and extravascular space of breast lesions.
摘要
直径范围为0.5至8微米的脂质壳全氟化碳(PFC)微泡已被用于制备。
经FDA批准,用于增强血液的对比度,以进行超声诊断成像。微观尺度
超声造影剂将它们限制在血流中,消除了增强的渗透性和滞留性
(EPR)在许多肿瘤中观察到。从现有的脂质壳微泡中产生纳米颗粒的能力
造影剂使我们能够利用这些药物的无毒配方,
使用任何已建立的用于配制靶向微泡的策略来制备纳米颗粒。微泡
靶向分泌型卷曲相关蛋白2(SFRP 2)的细胞在肿瘤和
SFRP 2在正常血管系统中高度表达,并且SFRP 2在多种乳腺癌中高度表达。我们和我们的同事
发现冷和增加的压力导致传统的气相超声造影剂凝结成
有足够的能量,这些非回声剂恢复到
常规超声造影剂。纳米液滴具有纳米颗粒固有的优点
癌症治疗的策略:通过EPR效应增强肿瘤中的被动积累,靶向
通过靶向部分辅助的肿瘤内的累积,以及减少的全身给药。激活纳米液滴
超声提供了高度的空间选择性,防止微尺度气泡重新进入
从而保持造影剂的高局部浓度。分子成像,
询问肿瘤内的间隙空间,扩大了成像的物理范围,
整个肿瘤体积中结合造影剂的密度,以及靶向肿瘤分子的额外机会
血管内皮细胞中没有我们认为,血管外分子成像与SFRP 2-
与微泡相比,靶向纳米液滴将增加检测乳腺癌的灵敏度
分子成像,同时保持减少错误诊断所需的分子特异性。一个关键
利用分子靶向的脂质壳全氟化碳纳米液滴的障碍是根本缺乏
了解它们在正常和肿瘤组织中的生物分布。我们建议将现有的、已建立的联合收割机
产生携带生物素和DNA的SFRP 2靶向和非靶向纳米液滴制剂的技术
标记,测定其循环半衰期,并使用生物素免疫组织化学检测或定量
我们独特的DNA有效载荷的聚合酶链反应测定,以表征这些液体的生物分布
在正常和肿瘤组织中的全氟化碳液滴。建立靶向纳米液滴交叉的能力
内皮细胞层利用现有的微泡造影剂,
药物,并通过开发一种新的,高度敏感的
灵敏的超声方法,该方法利用靶向分子成像的鉴别能力,
乳腺病变的血管和血管外间隙。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Accelerated blood clearance of targeted ultrasound contrast reduced molecular imaging signal intensity: Secreted Frizzled Related Protein-2 signal remained significantly higher than signal from either Vascular Endothelial Growth Factor Receptor-2 or alpha
目标超声造影剂的加速血液清除降低了分子成像信号强度:分泌的卷曲相关蛋白 2 信号仍然显着高于血管内皮生长因子受体 2 或 α 的信号
- DOI:10.1109/ultsym.2019.8925919
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Tsuruta,James;White,Rachel;Klauber-DeMore,Nancy;Dayton,PaulA
- 通讯作者:Dayton,PaulA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES K TSURUTA其他文献
JAMES K TSURUTA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES K TSURUTA', 18)}}的其他基金
Reversible vitamin A-dependent arrest of spermatogonia
可逆的维生素 A 依赖性精原细胞停滞
- 批准号:
6874405 - 财政年份:2003
- 资助金额:
$ 7.63万 - 项目类别:
Reversible vitamin A-dependent arrest of spermatogonia
可逆的维生素 A 依赖性精原细胞停滞
- 批准号:
6772495 - 财政年份:2003
- 资助金额:
$ 7.63万 - 项目类别:
Reversible vitamin A-dependent arrest of spermatogonia
可逆的维生素 A 依赖性精原细胞停滞
- 批准号:
7228881 - 财政年份:2003
- 资助金额:
$ 7.63万 - 项目类别:
Reversible vitamin A-dependent arrest of spermatogonia
可逆的维生素 A 依赖性精原细胞停滞
- 批准号:
6680614 - 财政年份:2003
- 资助金额:
$ 7.63万 - 项目类别:
Reversible vitamin A-dependent arrest of spermatogonia
可逆的维生素 A 依赖性精原细胞停滞
- 批准号:
7049394 - 财政年份:2003
- 资助金额:
$ 7.63万 - 项目类别:
相似国自然基金
基于Teach-back药学科普模式的慢阻肺患者吸入用药依从性及疗效研究
- 批准号:2024KP61
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Quench-Back保护的超导螺线管磁体失超过程数值模拟研究
- 批准号:51307073
- 批准年份:2013
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
- 批准号:
2338816 - 财政年份:2024
- 资助金额:
$ 7.63万 - 项目类别:
Continuing Grant
One-step reconstruction of plastic waste back to its constituent monomers (ONESTEP)
将塑料废物一步重建回其组成单体(ONESTEP)
- 批准号:
EP/Y003934/1 - 财政年份:2024
- 资助金额:
$ 7.63万 - 项目类别:
Research Grant
On the origin of very massive back holes
关于巨大背洞的起源
- 批准号:
DP240101786 - 财政年份:2024
- 资助金额:
$ 7.63万 - 项目类别:
Discovery Projects
Back to our roots: Re-activating Indigenous biocultural conservation
回到我们的根源:重新激活本土生物文化保护
- 批准号:
FT230100595 - 财政年份:2024
- 资助金额:
$ 7.63万 - 项目类别:
ARC Future Fellowships
Collaborative Research: FuSe: Indium selenides based back end of line neuromorphic accelerators
合作研究:FuSe:基于硒化铟的后端神经形态加速器
- 批准号:
2328741 - 财政年份:2023
- 资助金额:
$ 7.63万 - 项目类别:
Continuing Grant
Collaborative Research: NSFGEO-NERC: MEZCAL: Methods for Extending the horiZontal Coverage of the Amoc Latitudinally and back in time (MEZCAL)
合作研究:NSFGEO-NERC:MEZCAL:扩展 Amoc 纬度和时间回水平覆盖范围的方法 (MEZCAL)
- 批准号:
2409764 - 财政年份:2023
- 资助金额:
$ 7.63万 - 项目类别:
Standard Grant
Relationships Between Pain-Related Psychological Factors, Gait Quality, and Attention in Chronic Low Back Pain
慢性腰痛中疼痛相关心理因素、步态质量和注意力之间的关系
- 批准号:
10679189 - 财政年份:2023
- 资助金额:
$ 7.63万 - 项目类别:
The Role of VEGF in the Development of Low Back Pain Following IVD Injury
VEGF 在 IVD 损伤后腰痛发展中的作用
- 批准号:
10668079 - 财政年份:2023
- 资助金额:
$ 7.63万 - 项目类别:
Psilocybin and Affective Function in Chronic Lower Back Pain and Depression
裸盖菇素与慢性腰痛和抑郁症的情感功能
- 批准号:
10626449 - 财政年份:2023
- 资助金额:
$ 7.63万 - 项目类别:
Brain Mechanisms of Chronic Low-Back Pain: Specificity and Effects of Aging and Sex
慢性腰痛的脑机制:衰老和性别的特异性和影响
- 批准号:
10657958 - 财政年份:2023
- 资助金额:
$ 7.63万 - 项目类别: